|1.||Zaknoen, Sara: 4 articles (04/2014 - 02/2011)|
|2.||Moberly, James B: 3 articles (07/2008 - 02/2007)|
|3.||Syto, Mary: 2 articles (04/2014 - 02/2011)|
|4.||Milne, Ginger: 2 articles (04/2014 - 02/2011)|
|5.||Burrows, Francis J: 2 articles (09/2012 - 09/2012)|
|6.||Kirane, Amanda: 2 articles (09/2012 - 09/2012)|
|7.||Brekken, Rolf A: 2 articles (09/2012 - 09/2012)|
|8.||Toombs, Jason E: 2 articles (09/2012 - 09/2012)|
|9.||Kimura, Tomio: 2 articles (03/2008 - 01/2008)|
|10.||Fujiwara, Kosaku: 2 articles (03/2008 - 06/2007)|
03/01/2007 - "These data suggest that once-daily administration of CS-706 may be effective in providing relief of acute pain. "
11/01/2009 - "Phase IIa trial data indicated that apricoxib was a potent analgesic in the treatment of pain in postoperative dental surgery. "
01/06/2008 - "CS-706 ameliorated both yeast-induced inflammatory acute pain (ED(50)=0.0090 mg/kg) and adjuvant-induced chronic arthritic pain (ED(50)=0.30 mg/kg) in rats. "
11/01/2009 - "Apricoxib, a COX-2 inhibitor for the potential treatment of pain and cancer."
03/01/2007 - "This study evaluated the tolerability of single doses of CS-706 and compared the analgesic efficacy of CS-706 with that of celecoxib and placebo in the dental pain model. "
|2.||Pancreatic Neoplasms (Pancreatic Cancer)
11/01/2009 - "At the time of publication, phase II trials assessing apricoxib in combination with anticancer drugs in patients with breast, lung and pancreatic cancer were ongoing. "
09/15/2012 - "Apricoxib robustly reverses EMT and augments standard therapy without reducing microvessel density and warrants further clinical evaluation in patients with pancreatic cancer."
09/15/2012 - "Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancer."
09/15/2012 - "Here, we report that apricoxib, a novel COX-2 inhibitor in phase II clinical trials, significantly enhances the efficacy of gemcitabine/erlotinib in preclinical models of pancreatic cancer. "
|3.||Gastrointestinal Neoplasms (Gastrointestinal Cancer)
03/01/2011 - "At the 2011 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, preclinical evidence was presented regarding the efficacy of C4 compound against focal adhesion kinase (FAK) (Abstract #214), the role of the cyclooxygenase-2 (COX-2) inhibitor apricoxib in enhancing the efficacy of gemcitabine and erlotinib (Abstract #227) and the role of curcumin and ABT-888 (a poly-ADP ribose polymerase (PARP) inhibitor) as potent radiosensitizers (Abstracts #222 and #203). "
|4.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
09/01/2012 - "In vitro, either anchorage-independent growth conditions or forced EMT sensitized HT29 and non-small cell lung cancer cells to apricoxib by 50-fold, suggesting that the occurrence of EMT may actually increase the dependence of colon and lung carcinoma cells on COX-2. "
04/01/2014 - "A randomized, placebo-controlled, multicenter, biomarker-selected, phase 2 study of apricoxib in combination with erlotinib in patients with advanced non-small-cell lung cancer."
01/10/2015 - "Randomized, double-blind, placebo-controlled, multicenter phase II study of the efficacy and safety of apricoxib in combination with either docetaxel or pemetrexed in patients with biomarker-selected non-small-cell lung cancer."
09/15/2012 - "In each model examined, treatment with apricoxib resulted in vascular normalization without a decrease in microvessel density and promotion of an epithelial phenotype by tumor cells regardless of basal COX-2 expression. "
09/01/2012 - "Despite this, apricoxib significantly inhibited tumor cell proliferation and induced apoptosis without affecting blood vessel density, although it did promote vascular normalization. "
09/01/2012 - "Apricoxib was weakly cytotoxic toward naive HT29 cells in vitro but inhibited tumor growth markedly in vivo. "
09/01/2012 - "Epithelial-mesenchymal transition increases tumor sensitivity to COX-2 inhibition by apricoxib."
06/01/2007 - "Ultrasound image analysis as well as histologic evaluation revealed a significant therapeutic effect of CS-706 on the gallbladder tumors, either as reversion to a milder phenotype or inhibition of tumor progression. "
|1.||erlotinib (CP 358,774)
|4.||Cyclooxygenase 2 (Cyclooxygenase-2)
|5.||Focal Adhesion Protein-Tyrosine Kinases
|6.||Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)
|8.||2- ((R)- 2- methylpyrrolidin- 2- yl)- 1H- benzimidazole- 4- carboxamide
|1.||Drug Therapy (Chemotherapy)